A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression.

ABSTRACT:

Backgrounds

Pseudoprogression disease (PsPD) is commonly observed during glioblastoma (GBM) follow-up after adjuvant therapy. Because it is difficult to differentiate PsPD from true early progression of GBM, we have used a quantitative proteomics strategy to identify molecular signatures and develop predictive markers of PsPD.

Results

An initial screening of three PsPD and three GBM patients was performed, and from which 530 proteins with significant fold changes were identified. By conducting biological functional analysis of these proteins, we found evidence that the protein synthesis network and the cellular growth and proliferation network were most significantly affected. Moreover, six of the proteins (HNRNPK, ELAVL1, CDH2, FBLN1, CALU and FGB) involved in the two netwo

SUBMITTER: Zhang P 

PROVIDER: S-EPMC4393599 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature